Physician profile
Jennifer E Olson
NPI 1932202991
$1,994.33
in general payments reported to CMS, 2019-2025
30 companies · $159 in 2025
The $159 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.79 · 2020: $11.01 · 2021: $412 · 2022: $405 · 2023: $599 · 2024: $371 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.43 | 2021-2025 | |
| Novo Nordisk INC | $271.78 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $151.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $130.82 | 2022-2024 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $87.01 | 2022-2025 | Farxiga, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $82.49 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $55.11 | 2019-2022 | |
| Amgen INC. | $50.59 | 2019-2023 | Evenity, Prolia |
| Amarin Pharma, INC. | $46.63 | 2021 | |
| Pfizer INC. | $40.78 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.42 | 2022-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.91 | 2022-2023 | |
| Insulet Corporation | $33.39 | 2024 | Omnipod |
| Abbott Laboratories | $31.28 | 2024-2025 | Eterna, Freestyle Libre 3 |
| Exact Sciences Corporation | $29.86 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $27.44 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $25.98 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Inari Medical, INC. | $22.60 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $21.53 | 2023 | |
| Eisai INC. | $21.02 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.63 | 2022 | |
| Astellas Pharma US INC | $15.61 | 2024 | Veozah |
| Dexcom, INC. | $14.75 | 2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $14.27 | 2023 | Linzess |
| Boston Scientific Corporation | $14.07 | 2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $14.03 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.01 | 2022 | |
| Phathom Pharmaceuticals, INC. | $7.95 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.